US EditionTransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
- TransCode Therapeutics, Inc. Has closed a direct offering of 10,250,000 shares and warrants for $0.98 each, raising approximately $10 million before fees and expenses, as announced on March 25, 2025.
- The funds will primarily support product development activities, including clinical trials for TTX-MC138, the company’s lead therapeutic candidate, according to TransCode.
- ThinkEquity was the sole placement agent for the offering made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission .
- TransCode specializes in RNA therapeutics and aims to treat metastatic cancer, particularly targeting tumors that overexpress microRNA-10b.
Insights by Ground AI
Does this summary seem wrong?
43 Articles
43 Articles
All
Left
2
Center
14
Right
4
hartfordcitynewstimes.com+42 Reposted by 42 other sources
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced sale of 10,250,000 shares…
·Hartford City, United States
Read Full ArticleCoverage Details
Total News Sources43
Leaning Left2Leaning Right4Center14Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
C 70%
R 20%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
